Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Keppra for Cervical Dystonia
NCT00760318 · University of South Florida · PHASE2 · terminated · last registry update 2018-11-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decided to stop enrollment to review data.” | – | Registry record, University of South Florida |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SV2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-11-21Phase 3 first posted: Lady Hardinge Medical College, Levetiracetam (NCT04172311)
- 2019-08-21Results posted on the registry: Richard H. Haas, Intravenous levetiracetam + Intravenous phenobarbital (NCT01720667)
- 2019-07-12Results posted on the registry: Washington University School of Medicine, a drug against SV2A (NCT01137110)
- 2019-06-10Results posted on the registry: UCB Japan Co. Ltd., Levetiracetam (NCT00160615)
- 2019-05-28Results posted on the registry: UCB Biopharma S.P.R.L., Brivaracetam + Lorazepam (NCT03021018)
- 2019-04-17Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cyclophosphamide + Fludarabine (NCT00489281)
- 2019-04-17Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cyclophosphamide + Fludarabine (NCT00489281)
- 2019-01-31Results posted on the registry: UCB Pharma, Placebo + Brivaracetam (NCT00160667)
- 2018-12-05Results posted on the registry: UCB PHARMA Inc. (US), Brivaracetam (NCT00150800)
- 2018-11-14Phase 3 first posted: UCB Biopharma SRL, Padsevonil + Placebo (NCT03739840)
- 2018-10-01Results posted on the registry: UCB Pharma SA, Levetiracetam (NCT00150813)
- 2018-09-26Phase 3 first posted: UCB Biopharma S.P.R.L., Brivaracetam (NCT03685630)
- 2018-08-22Results posted on the registry: UCB Pharma, Brivaracetam (NCT00175825)
- 2018-08-07Results posted on the registry: Massachusetts General Hospital, levetiracetam + Lamotrigine (NCT00916149)
- 2018-07-11Also stopped (terminated): UCB Pharma, Brivaracetam + Brivaracetam (NCT00698581)
- 2018-07-11Also stopped (terminated): UCB BIOSCIENCES, Inc., Brivaracetam intravenous solution + Brivaracetam oral tablets (NCT02088957)
- 2018-07-11Also stopped (terminated): UCB Pharma, Brivaracetam + Brivaracetam (NCT00699283)
- 2018-07-09Phase 3 first posted: Rosenfeld, William E., M.D., BRV vs LEV in randomized double blinded, crossover fashion (NCT03580707)
- 2018-06-07Also stopped (withdrawn): Medical University of South Carolina, levetiracetam (NCT00627133)
- 2018-04-23Results posted on the registry: UCB Pharma, Brivaracetam (NCT00761774)
- 2018-02-28Also stopped (terminated): Hannover Medical School, Phenobarbital + Phenytoin (NCT02374567)
- 2017-12-28Also stopped (terminated): Masonic Cancer Center, University of Minnesota, Allopurinol + Fludarabine (NCT01464359)
- 2017-12-18Also stopped (terminated): Thomas Jefferson University, phenytoin + valproate (NCT00774306)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision